BRAF and melanoma: GSK 2118436 is an ATP competitive, reversible inhibitor of the mutant BRAFV600E/K/D (IC50 0.5, 0.6, 1.9 nM, respectively), wt BRAF (IC50 12 nM) and CRAF (IC50 5 nM) kinases with promising preclinical efficacy data in melanoma.